{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:43:02Z","timestamp":1791571382324,"version":"4.3.4"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.ejca.2016.11.027","type":"journal-article","created":{"date-parts":[[2016,12,24]],"date-time":"2016-12-24T10:11:01Z","timestamp":1482574261000},"page":"54-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"C","title":["Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients"],"prefix":"10.1016","volume":"72","author":[{"given":"E.","family":"Carton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3864-6224","authenticated-orcid":false,"given":"G.","family":"Noe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9764-0845","authenticated-orcid":false,"given":"O.","family":"Huillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Golmard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Giroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cessot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6427-6813","authenticated-orcid":false,"given":"N.E.B.","family":"Saidu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Peyromaure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Zerbib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Narjoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Guibourdenche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Goldwasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Blanchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejca.2016.11.027_bib1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"issue":"15","key":"10.1016\/j.ejca.2016.11.027_bib2","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1158\/0008-5472.CAN-12-4414","article-title":"A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer","volume":"73","author":"Mitsiades","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2016.11.027_bib3","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.steroids.2014.12.021","article-title":"CYP17A1 inhibitors in castration-resistant prostate cancer","volume":"95","author":"Gomez","year":"2015","journal-title":"Steroids"},{"issue":"6","key":"10.1016\/j.ejca.2016.11.027_bib4","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s00280-012-1865-3","article-title":"Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men","volume":"69","author":"Acharya","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.ejca.2016.11.027_bib5","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/00498254.2012.721022","article-title":"A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects","volume":"43","author":"Acharya","year":"2013","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejca.2016.11.027_bib6","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ejca.2016.11.027_bib7","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2016.11.027_bib8","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2016.11.027_bib9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2016.11.027_bib10","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejca.2016.11.027_bib11","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1158\/1078-0432.CCR-14-1961","article-title":"Improvements in radiographic progression-free survival stratified by ERG gene status in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate","volume":"21","author":"Attard","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ejca.2016.11.027_bib12","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/annonc\/mdv257","article-title":"Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015","volume":"26","author":"Gillessen","year":"2015","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2016.11.027_bib13","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s40262-014-0178-6","article-title":"Population pharmacokinetic analysis of abiraterone in chemotherapy-na\u00efve and docetaxel-treated patients with metastatic castration-resistant prostate cancer","volume":"53","author":"Stuyckens","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ejca.2016.11.027_bib14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jchromb.2015.03.001","article-title":"A HPLC-fluorescence method for the quantification of abiraterone in plasma from patients with metastatic castration-resistant prostate cancer","volume":"989","author":"Belleville","year":"2015","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"issue":"7","key":"10.1016\/j.ejca.2016.11.027_bib15","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J ClinOncol"},{"key":"10.1016\/j.ejca.2016.11.027_bib16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl. 5","key":"10.1016\/j.ejca.2016.11.027_bib17","article-title":"Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Parker","year":"2015","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2016.11.027_bib18","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.ejca.2014.04.013","article-title":"Therapeutic drug monitoring in cancer-are we missing a trick?","volume":"50","author":"Bardin","year":"2014","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2016.11.027_bib19","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.ejca.2014.04.015","article-title":"Review of therapeutic drug monitoring of anticancer drugs part two-targeted therapies","volume":"50","author":"Widmer","year":"2014","journal-title":"Eur J Cancer"},{"issue":"28","key":"10.1016\/j.ejca.2016.11.027_bib20","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"Attard","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2016.11.027_bib21","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.7_suppl.188","article-title":"Initial results from a phase II study of increased-dose abiraterone acetate in patients with castration resistant prostate cancer","volume":"33","author":"Friedlander","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2016.11.027_bib22","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1016\/S1470-2045(15)70033-1","article-title":"Sequencing of agents in castration-resistant prostate cancer","volume":"16","author":"Lorente","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2016.11.027_bib23","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1158\/1078-0432.CCR-14-1220","article-title":"Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors","volume":"21","author":"Chen","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"7560","key":"10.1016\/j.ejca.2016.11.027_bib24","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nature14406","article-title":"Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer","volume":"523","author":"Li","year":"2015","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.ejca.2016.11.027_bib25","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","article-title":"Quantification of lean bodyweight","volume":"44","author":"Janmahasatian","year":"2005","journal-title":"ClinPharmacokinet"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804916326053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804916326053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T11:53:32Z","timestamp":1536148412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804916326053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":25,"alternative-id":["S0959804916326053"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2016.11.027","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2016.11.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}